Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient
Launched by CHIESI FARMACEUTICI S.P.A. · Mar 21, 2019
Trial Information
Current as of May 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adults aged ≥ 40 years, Chinese ethnicity
- • Patients with COPD diagnosed at least 12 months before the screening visit.
- • A smoking history of at least 10 pack years
- • Post-bronchodilator FEV1 \< 50% of the predicted normal value
- • Post-bronchodilator FEV1/FVC ratio \< 0.7
- • One exacerbation in the 12 months prior the screening visit
- Exclusion Criteria:
- • Patients requiring OCS/antibiotics/PDE inhibitors in the 4 weeks prior to screening
- • COPD exacerbation requiring OCS/antibiotics or hospitalization during the run-in period
- • Known respiratory disorders other than COPD
- • Diagnosis of asthma
About Chiesi Farmaceutici S.P.A.
Chiesi Farmaceutici S.p.A. is a global pharmaceutical company headquartered in Parma, Italy, specializing in the research, development, and commercialization of innovative therapeutic solutions. With a strong focus on respiratory diseases, neonatology, and rare diseases, Chiesi is dedicated to improving patient outcomes through advanced science and technology. The company operates in more than 30 countries and invests significantly in R&D to enhance its product portfolio and expand its global reach. Committed to sustainability and social responsibility, Chiesi adheres to the highest ethical standards in clinical trials and strives to address unmet medical needs with cutting-edge therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hefei, Anhui, China
Hefei, Anhui, China
Beijing, Beijing, China
Beijing, Beijing, China
Beijing, Beijing, China
Beijing, Beijing, China
Beijing, Beijing, China
Chongqing, Chongqing, China
Chongqing, Chongqing, China
Fuzhou, Fujian, China
Lanzhou, Gansu, China
Dongguan, Guangdong, China
Foshan, Guangdong, China
Guangzhou, Guangdong, China
Guangzhou, Guangdong, China
Guangzhou, Guangdong, China
Guangzhou, Guangdong, China
Guangzhou, Guangdong, China
Zhanjiang, Guangdong, China
Nanning, Guangxi, China
Zunyi, Guizhou, China
Haikou, Hainan, China
Haikou, Hainan, China
Zhengzhou, Henan, China
Zhengzhou, Henan, China
Changsha, Hunan, China
Hengyang, Hunan, China
Xiangtan, Hunan, China
Hohhot, Inner Mongolia, China
Nanjing, Jiangsu, China
Nanjing, Jiangsu, China
Wuxi, Jiangsu, China
Xuzhou, Jiangsu, China
Nanchang, Jiangxi, China
Changchun, Jilin, China
Changchun, Jilin, China
Dalian, Liaoning, China
Jinan, Shandong, China
Shanghai, Shanghai, China
Shanghai, Shanghai, China
Shanghai, Shanghai, China
Shanghai, Shanghai, China
Shanghai, Shanghai, China
Shanghai, Shanghai, China
Shanghai, Shanghai, China
Taiyuan, Shanxi, China
Taiyuan, Shanxi, China
Chengdu, Sichuan, China
Tianjin, Tianjin, China
Tianjin, Tianjin, China
Hangzhou, Zhejiang, China
Taizhou, Zhejiang, China
Wenzhou, Zhejiang, China
Patients applied
Trial Officials
Professor Fuqiang WEN, M.D., Ph.D.
Principal Investigator
West China Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials